Project Grant R34DA058494
Award Date
5/15/24
Completion Date
4/30/27
Dollars Obligated
$660K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $761,711 to Virginia Commonwealth University (VCU) to investigate the role of the orexin system in the intersection of opioid use disorder (OUD) and insomnia. The 5-year study will use the NIDA Phenotyping Battery to examine how pharmacologically antagonizing the orexin system with the FDA-approved drug lemborexant affects symptoms related to...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $936,880 to Yale University to investigate the neural mechanisms connecting deficient sleep and smoking relapse. The study aims to examine how cognitive behavioral therapy for insomnia (CBT-I) can ameliorate negative emotions, improve self-control, and promote smoking cessation. Researchers will recruit 114 treatment-seeking adults...
This $24,556,175 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a Phase III randomized controlled trial to evaluate the efficacy and safety of suvorexant, a dual-orexin receptor antagonist, in treating insomnia among individuals with opioid use disorder (OUD) who are receiving long-term medication for OUD treatment (MOUD) such as buprenorphine or methadone. The study, led by The Johns...
This $2,729,018 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and evaluation of a mobile health intervention for individuals with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during the critical community re-entry period following residential OUD treatment. The key products to be delivered through this grant include a rigorously developed...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $355,414 to Yale University to implement and evaluate a digital therapeutic for addressing substance use disorders (SUDs), including opioid use disorder (OUD), among incarcerated individuals. The key objectives are to: Assess attitudes and perceptions of using a digital therapeutic for SUDs, as well as barriers and facilitators to implementing the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,739 to Attune Neurosciences, Inc. to develop a wearable, head-worn low-intensity focused ultrasound (LIFU) device for enhancing sleep in individuals with substance use disorder (SUD), including opioid use disorder (OUD). The key products and services to be delivered under this Phase I Small Business Innovation Research (SBIR) grant include...
The National Institute on Drug Abuse (NIDA) awarded a 5-year, $1.2M Project Grant under CFDA Program 93.279 - Drug Use and Addiction Research Programs to the University of Rochester. The grant is titled "Addressing Perceived Social Isolation as a Novel Therapeutic Target Among Individuals with OUD Using Telehealth CBT". The project aims to assess the efficacy of a cognitive-behavioral therapy (CBT) intervention delivered via telehealth to decrease perceived social isolation and...
The National Institute on Drug Abuse (NIDA) awarded a $581,914 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Texas A&M University System Health Science Center. The 5-year grant, effective August 1, 2024, seeks to uncover the biological basis for why sleep apnea patients are more sensitive to opioid-induced respiratory depression (OIRD), which is a leading cause of opioid overdose deaths. The research will investigate how oxytocin neurotransmission from...
This $385,000 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a comprehensive analysis of treatment patterns, outcomes, and predictive factors for patients with co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). The research aims to assess the effectiveness of integrated treatment approaches, including first-line OUD and AUD medications as well as glucagon-like peptide-1...
This $1,534,938 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a randomized controlled trial to evaluate an immersive mindfulness virtual reality (VR) intervention for chronic pain and opioid use disorder (OUD) in opioid treatment programs. The grant will support enrollment and randomization of 185 participants with chronic pain and OUD at opioid treatment programs in the Bronx, New York to receive...